 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Veralipride" – news ·newspapers ·books ·scholar ·JSTOR(July 2024) (Learn how and when to remove this message) |
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Agreal, Agradil |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.060.376 |
| Chemical and physical data | |
| Formula | C17H25N3O5S |
| Molar mass | 383.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Veralipride (Agreal,Agradil) is anatypical antipsychotic of thebenzamide class. It is used for the treatment ofvasomotor symptoms associated withmenopause. It is aD2 receptor antagonist and it inducesprolactin secretion without any estrogenic or progestagenic effects.[2] It was first authorised for use in 1979. However, Veralipride has never gained approval in the United States.
The women who took it, in addition to extra-pyramidal effects, experienced an aggressive form of depression that resulted in death by suicide for some. The Sanofi laboratory, despite knowing its side effects, allowed women to continue taking it for a considerable amount of time. For this reason, its sale was banned in all countries except Mexico, which allowed its sale to continue for at least 15 years.
In September 2006, veralipride was withdrawn from the Spanish market. As a result, theEuropean Commission referred the matter to theEuropean Medicines Agency (EMA). In July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[3]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |